TRAFALGAR INTERNATIONAL, INC.

GCAN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-331.6K $-179.0K $-188.4K $-360.3K $-602.2K $-951.2K $-1.6M $-839.1K
Depreciation & Amortization
Depreciation
Amortization $417 $5.0K $5.0K $20.0K $10.3K
Stock-Based Compensation $1.8K $88.1K
Net Cash from Operating Activities $-60.2K $-109.5K $-103.2K $-107.5K $-235.4K $-289.6K $-285.2K $-100.1K
Investing Activities
Capital Expenditures
Business Acquisitions $25.0K
Net Cash from Investing Activities $-61.8K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $3.6K $500.0K $439.7K $250.0K $160.0K
Net Change in Cash $-56.6K $-109.5K $-103.2K $-107.5K $264.6K $88.3K $-35.2K $59.9K
Free Cash Flow
← Newer Page 1 of 2 Older →